Yuyu Pharma, Inc.

Symbol: 000220.KS

KSC

4650

KRW

Market price today

  • -11.1660

    P/E Ratio

  • 0.0861

    PEG Ratio

  • 75.25B

    MRK Cap

  • 0.02%

    DIV Yield

Yuyu Pharma, Inc. (000220-KS) Stock Price & Analysis

Shares Outstanding

16.18M

Gross Profit Margin

0.35%

Operating Profit Margin

-0.00%

Net Profit Margin

-0.05%

Return on Assets

-0.03%

Return on Equity

-0.06%

Return on Capital Employed

-0.00%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO:Mr. Wonsang Yu
Full-time employees:318
City:Seoul
Address:Yuyu Building
IPO:2000-01-04
CIK:

Yuyu Pharma, Inc. develops and markets pharmaceutical products. The company offers various prescription drugs, including osteoporosis, brainbone metabolism-hypocalcemia improvement, cerebral and peripheral circulatory disturbance, tromboembolism, respiratory organ, hypertension, pulmonary tuberculosis therapy, arthrifuge, diabetic neuropathy therapy, eczematous dermatitis drugs, and other circulatory system drugs, as well as antibiotics and skeletal muscle relaxants. It also provides non-prescription drugs and health supplements. The company was formerly known as YuYu Inc. and changed its name to Yuyu Pharma, Inc. in May 2008. Yuyu Pharma, Inc. was founded in 1941 and is headquartered in Seoul, South Korea.

General Outlook

In simple terms, Yuyu Pharma, Inc. has 16.183 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.352% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.001%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.050%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.034% return, is a testament to Yuyu Pharma, Inc.'s adeptness in optimizing resource deployment. Yuyu Pharma, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.060%. Furthermore, the proficiency of Yuyu Pharma, Inc. in capital utilization is underscored by a remarkable -0.001% return on capital employed.

Stock Prices

Yuyu Pharma, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $5250, while its low point bottomed out at $5040. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Yuyu Pharma, Inc.'s stock market.

Liquidity Ratios

Analyzing 000220.KS liquidity ratios reveals its financial health of the firm. The current ratio of 203.29% gauges short-term asset coverage for liabilities. The quick ratio (113.67%) assesses immediate liquidity, while the cash ratio (61.24%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio203.29%
Quick Ratio113.67%
Cash Ratio61.24%

Profitability Ratios

000220.KS profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -4.05% underscores its earnings before tax deductions. The effective tax rate stands at -1.77%, revealing its tax efficiency. The net income per EBT, 122.74%, and the EBT per EBIT, 3283.55%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -0.12%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-4.05%
Effective Tax Rate-1.77%
Net Income per EBT122.74%
EBT per EBIT3283.55%
EBIT per Revenue-0.12%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 2.03, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations. Meanwhile, a 1 cash conversion cycle and 561.08% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding114
Days of Inventory Outstanding181
Operating Cycle246.17
Days of Payables Outstanding45
Cash Conversion Cycle201
Receivables Turnover5.61
Payables Turnover8.12
Inventory Turnover2.02
Fixed Asset Turnover1.69
Asset Turnover0.69

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 29.65, and free cash flow per share, -285.89, depict cash generation on a per-share basis. The cash per share value, 1999.31, showcases liquidity position.

cards.indicatorcards.value
Operating Cash Flow per Share29.65
Free Cash Flow per Share-285.89
Cash per Share1999.31
Free Cash Flow to Operating Cash Flow Ratio-9.64
Cash Flow Coverage Ratio0.01
Short Term Coverage Ratio0.02
Capital Expenditure Coverage Ratio0.09
Dividend Paid and Capex Coverage Ratio0.09
Dividend Payout Ratio0.02

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 19.69%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.35, we discern the balance between debt and equity financing. The long-term debt to capitalization, 10.84%, and total debt to capitalization, 25.81%, ratios shed light on its capital structure. An interest coverage of -0.05 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio19.69%
Debt Equity Ratio0.35
Long Term Debt to Capitalization10.84%
Total Debt to Capitalization25.81%
Interest Coverage-0.05
Cash Flow to Debt Ratio0.01
Company Equity Multiplier1.77

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 8434.35, provides a glimpse into top-line earnings distributed across each share. Net income per share, -441.41, reflects the portion of profit attributed to each share. The book value per share, 6896.24, represents the net asset value distributed per share, while the tangible book value per share, 7135.99, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share8434.35
Net Income Per Share-441.41
Book Value Per Share6896.24
Tangible Book Value Per Share7135.99
Shareholders Equity Per Share6896.24
Interest Debt Per Share2555.95
Capex Per Share-313.88

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -1.20%, indicates top-line expansion, while the gross profit growth, -12.77%, reveals profitability trends. EBIT growth, -208.27%, and operating income growth, -208.27%, offer insights into operational profitability progression. The net income growth, -62.27%, showcases bottom-line expansion, and the EPS growth, -65.38%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth-1.20%
Gross Profit Growth-12.77%
EBIT Growth-208.27%
Operating Income Growth-208.27%
Net Income Growth-62.27%
EPS Growth-65.38%
EPS Diluted Growth-65.38%
Weighted Average Shares Growth-1.89%
Weighted Average Shares Diluted Growth-1.89%
Dividends per Share Growth0.32%
Operating Cash Flow Growth113.47%
Free Cash Flow Growth63.83%
10-Year Revenue Growth per Share43.43%
5-Year Revenue Growth per Share44.96%
3-Year Revenue Growth per Share6.71%
10-Year Operating CF Growth per Share170.15%
5-Year Operating CF Growth per Share-87.94%
3-Year Operating CF Growth per Share123.99%
10-Year Net Income Growth per Share-347.99%
5-Year Net Income Growth per Share-256.81%
3-Year Net Income Growth per Share-327.13%
10-Year Shareholders Equity Growth per Share1.86%
5-Year Shareholders Equity Growth per Share14.80%
3-Year Shareholders Equity Growth per Share-25.14%
10-Year Dividend per Share Growth per Share36.12%
3-Year Dividend per Share Growth per Share0.53%
Receivables Growth-3.38%
Inventory Growth10.85%
Asset Growth1.54%
Book Value per Share Growth-2.12%
Debt Growth0.33%
R&D Expense Growth-16.62%
SGA Expenses Growth99.30%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 95,835,808,700, captures the company's total value, considering both debt and equity. Income quality, -0.12, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.03, gauges operational efficiency, while the research and development to revenue, 5.24%, highlights investment in innovation. The ratio of intangibles to total assets, 2.15%, indicates the value of non-physical assets, and capex to operating cash flow, -608.53%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value95,835,808,700
Income Quality-0.12
Sales General and Administrative to Revenue0.03
Research and Development to Revenue5.24%
Intangibles to Total Assets2.15%
Capex to Operating Cash Flow-608.53%
Capex to Revenue-3.72%
Capex to Depreciation-91.06%
Graham Number8276.00
Return on Tangible Assets-3.70%
Graham Net Net-312.68
Working Capital51,621,343,307
Tangible Asset Value116,087,958,883
Net Current Asset Value23,738,673,984
Average Receivables24,881,657,822
Average Payables13,396,146,500
Average Inventory41,992,105,837
Days Sales Outstanding65
Days Payables Outstanding44
Days of Inventory On Hand178
ROIC-0.51%
ROE-0.06%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 0.68, and the price to book ratio, 0.68, reflect the market's valuation relative to the company's book value. The price to sales ratio, 0.55, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -16.46, and price to operating cash flows, 158.69, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio0.68
Price to Book Ratio0.68
Price to Sales Ratio0.55
Price Cash Flow Ratio158.69
Price Earnings to Growth Ratio0.09
Enterprise Value Multiple2.50
Price Fair Value0.68
Price to Operating Cash Flow Ratio158.69
Price to Free Cash Flows Ratio-16.46
Price to Tangible Book Ratio0.78
Enterprise Value to Sales0.70
Enterprise Value Over EBITDA19.73
EV to Operating Cash Flow114.21
Earnings Yield-8.25%
Free Cash Flow Yield-4.90%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Yuyu Pharma, Inc. (000220.KS) on the KSC in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -11.166 in 2024.

What is the ticker symbol of Yuyu Pharma, Inc. stock?

The ticker symbol of Yuyu Pharma, Inc. stock is 000220.KS.

What is company IPO date?

IPO date of Yuyu Pharma, Inc. is 2000-01-04.

What is company current share price?

Current share price is 4650.000 KRW.

What is stock market cap today?

The market cap of stock today is 75249652650.000.

What is PEG ratio in 2024?

The current 0.086 is 0.086 in 2024.

What is the number of employees in 2024?

In 2024 the company has 318.